METHODS: To explore the role of the USP43/E2F1/NSDHL pathway in GEM resistance in BLCA, we employed integrated analytical approaches including gene expression profiling, biochemical assays, xenograft models, among others. The gene discussed is E2F1; the disease is bladder transitional cell carcinoma.